Altiratinib - Deciphera Pharmaceuticals
Alternative Names: DCC-22701; DCC-2701; DP-5164Latest Information Update: 14 Jun 2024
At a glance
- Originator Deciphera Pharmaceuticals
- Class Amides; Antineoplastics; Cyclopropanes; Dicarboxylic acids; Pyridines; Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto-oncogene protein c-met inhibitors; TIE-2 receptor antagonists; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glioblastoma; Solid tumours
Most Recent Events
- 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
- 28 Feb 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Glioblastoma in USA (PO, Tablet)